With CVR, Pacira’s deal for Flexion could nearly double in size
Analgesics company Pacira adds marketed osteoarthritis therapy, with more upside for Flexion shareholders
Pacira’s takeout of Flexion gives the pain management company an osteoarthritis asset that extends its commercial reach while building in further upside for Flexion’s shareholders via a CVR.
Monday’s deal gives Pacira BioSciences Inc. (NASDAQ:PCRX) possession of Zilretta sustained-release triamcinolone acetonide, which Flexion Therapeutics Inc. (NASDAQ:FLXN) has marketed since October 2017. The product, approved to treat osteoarthritis pain of the knee, generated $85.6 million in 2020 revenues, and $52.8 million over the first six months of 2021...
BCIQ Target Profiles
Sodium voltage-gated channel alpha subunit 9 (Nav1.7) (SCNA9)